Business Wire

TX-ZILLIANT

Share
Zilliant Introduces Real-Time Pricing Engine™ to Deliver Dynamic Pricing Capabilities Needed in the Digital Age

Zilliant , the industry leader in intelligent B2B price optimization, price management and sales guidance software, today introduced the Real-Time Pricing Engine™, a new product that enables business-to-business (B2B) companies to calculate and deliver prices in real-time to any commercial system.

Executing pricing logic and delivering prices in real-time to digital commerce channels is often beyond the capabilities of many companies’ existing pricing engines. The Zilliant Real-Time Pricing Engine™ meets the growing need for a faster, more robust way of handling the pricing demands of complex omnichannel B2B companies. The solution’s high-availability, high-performance REST API with 99.99% guaranteed uptime instantaneously executes complex pricing logic, and performs complex calculations, including external data lookups, to deliver prices to any ERP, CRM, CPQ, eCommerce platform or mobile application.

“We set out to help customers power intelligent commerce in the digital age, and the Real-Time Pricing Engine™ is one of the most effective tools to accomplish that,” said Zilliant President and Chief Executive Officer Greg Peters. “Companies seeking to be more dynamic in their approach to pricing are no longer constrained by the limitations of legacy systems. With real-time pricing, they can execute complex pricing calculations in milliseconds.”

The Rise of B2B Digital Commerce Calls for Real-Time Pricing

Gartner has mentioned pricing as one of the core functional components of a commerce platform. In the report, “Harness the Core Capabilities of a Digital Commerce Platform ,” Gartner states pricing “may need to be real-time if pricing is highly dynamic. Real-time integrations to ERP are fraught with performance risks, so often, caching layers or other forms of ERP protection must be in place. [The] interaction of pricing with promotional engines can be complex and must be approached with caution. Pricing management is an area of growing sophistication and disruption. Third-party point solutions are often required to take advantage of innovations.”1

“36% of B2B buyers say an inability to get the best price online is a significant barrier to doing more business via the digital commerce channel,” stated Gartner Senior Research Director, Mark Lewis in a report.2 “To unblock those potential buyers, it’s essential to employ an AI-driven, real-time and value-based pricing engine, which can consider competition, customer profile, stock availability, etc. to come up with the best price for each buying situation. Not all customers have to see the same prices. This model is employed successfully to optimize the profits of airlines, hotels and car rental companies. In this situation, customers must understand that they are seeing a spot price that can go up or down. Most importantly, they must get the same spot price regardless of channel interaction.”2

Zilliant Real-Time Pricing Engine™ ─ in conjunction with Zilliant Price Manager™ ─ meets the need for a third-party point solution to effectively manage and house pricing logic and reliably calculate and deliver the correct price for a customer in real-time. In practice, each transaction or quote request triggers a complex pricing build or look up to determine the right price, along with its attendant taxes, fees and discounts. Further, the proliferation of scenarios that require on-demand pricing is vast; it’s not uncommon for tens of thousands of pricing requests to flow through a company in various channels daily. Companies can significantly increase the speed, accuracy and consistency of pricing – as well as the pricing negotiation process – by using the Real-Time Pricing Engine™ and Price Manager™ to automate negotiations, counteroffers and approvals based on pre-defined parameters.

Learn more about real-time pricing and the Zilliant Real-Time Pricing Engine™ .

1 Gartner, “Harness the Core Capabilities of a Digital Commerce Platform,” Mike Lowndes, Christina Klock, published September 4, 2019 and refreshed on February 9, 2021.

2 Gartner, “Increase Profits and Delight Buyers by Becoming a Digital-First, Omnichannel B2B Seller,” Mark Lewis, April 1, 2021.

Gartner Disclaimer:

GARTNER is registered trademark and service mark of Gartner, Inc. and/or its affiliates in the U.S. and internationally and is used herein with permission. All rights reserved.

About Zilliant

Zilliant powers intelligent commerce for B2B companies by connecting their commercial strategies with effective execution. Our industry-leading price optimization and management and sales guidance software enables profitable growth by transforming the way our customers use data to price and sell in traditional and digital channels. Zilliant’s data science, cloud-native software and passion for customer success delivers the highest ROI, fastest time to value and highest customer satisfaction. Learn more about how Zilliant helps power intelligence commerce at www.zilliant.com .

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Deciphera Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study of ROMVIMZA™ (vimseltinib) in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the European Society for Medical Oncology Congress 202518.10.2025 13:00:00 CEST | Press release

– Vimseltinib demonstrated statistically significant and clinically meaningful benefit vs placebo in antitumor response – Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the two-year efficacy and safety results from its MOTION Phase 3 study of vimseltinib in patients with TGCT in cases where surgical removal of the tumor is not an option will be presented as a poster during the 2025 European Society for Medical Oncology Congress (ESMO), taking place October 17-21 in Berlin, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251018921529/en/ “These long-term Phase 3 MOTION results add to the established body of evidence supporting vimseltinib as a best-in-class treatment for TGCT,” said Matthew L. Sherman, M.D., Chief Medical Officer of Deciphera. “TGCT often causes debilitating pain, stiffness and impaired mobility and these results demonstrate the dura

ProAmpac Acquires International Paper’s Bag Converting Operations17.10.2025 16:09:00 CEST | Press release

ProAmpac, a global leader in flexible packaging and material science, has acquired the bag converting operations of International Paper (“IP”), a global leader in sustainable packaging. The acquisition expands ProAmpac’s converting capabilities, further advancing the company’s Fiberization of Packaging® strategy and enhancing its ability to deliver customized bag solutions for the grocery, convenience store, and quick-service restaurant markets. “Global demand for reliable, recyclable paper packaging continues to grow rapidly amid evolving consumer expectations and market trends redefining recyclability,” stated Greg Tucker, ProAmpac founder, vice chairman, and chief executive officer. “ProAmpac’s acquisition of IP’s bag operation supports our Fiberization of Packaging initiatives, helping us better serve customers by extending our expertise in material science to the US west coast with additional capabilities and redundancies,” continued Tucker. “IP’s bag business is strong, being bui

Pimicotinib Treatment Demonstrates Deep and Durable Tumor Responses and Continued Improvements in Pain and Function for Patients with TGCT17.10.2025 16:00:00 CEST | Press release

With median follow-up of 14.3 months, pimicotinib demonstrated increasing ORR over time, from 54% at Week 25 to 76.2%Global Phase 3 MANEUVER study demonstrated ongoing improvements in key secondary endpoints including pain and functionApplication for marketing authorization under review by China National Medical Products Administration (NMPA), with additional applications planned in the U.S. and other marketsNot intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced the presentation of longer-term results from the global Phase 3 MANEUVER trial evaluating pimicotinib, an investigational colony stimulating factor-1 receptor (CSF-1R) inhibitor in development by Abbisko Therapeutics Co., Ltd., for the treatment of patients with tenosynovial giant cell tumor (TGCT). This latest analysis showed that, with a median follow-up of 14.3 months, the objective response rate (ORR) for people treated with pimicotinib from the beginning of the stud

Vertex Announces Progress in Povetacicept Development Program and Presentation of New Data at American Society of Nephrology Kidney Week17.10.2025 15:04:00 CEST | Press release

- Food and Drug Administration grants rolling review of Biologics License Application for povetacicept in IgA nephropathy; Vertex to submit first module before end of year - - Second pivotal development program of povetacicept underway with Phase 2b/3 trial initiation in primary membranous nephropathy - - Updated data from RUBY-3 trial of povetacicept accepted for late breaking oral presentation; inaxaplin study design and APOL1-mediated kidney disease related data accepted for poster presentation - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced several important updates across its development program for povetacicept (pove), an investigational recombinant fusion protein therapeutic and dual antagonist of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines. Pove has demonstrated best-in-class potential in IgA nephropathy (IgAN) and primary membranous nephropathy (pMN) and has pipeline-in-a-product potential across a range of B c

Qualcomm Announces Quarterly Cash Dividend17.10.2025 15:00:00 CEST | Press release

Qualcomm Incorporated (NASDAQ: QCOM) today announced a quarterly cash dividend of $0.89 per common share, payable on December 18, 2025, to stockholders of record at the close of business on December 4, 2025. About Qualcomm Qualcomm relentlessly innovates to deliver intelligent computing everywhere, helping the world tackle some of its most important challenges. Building on our 40 years of technology leadership in creating era-defining breakthroughs, we deliver a broad portfolio of solutions built with our leading-edge AI, high-performance, low-power computing, and unrivaled connectivity. Our Snapdragon® platforms power extraordinary consumer experiences, and our Qualcomm Dragonwing™ products empower businesses and industries to scale to new heights. Together with our ecosystem partners, we enable next-generation digital transformation to enrich lives, improve businesses, and advance societies. At Qualcomm, we are engineering human progress. Qualcomm Incorporated includes our licensing

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye